Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
2000-06-06
2000-11-21
Rose, Shep K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
A61K 31505
Patent
active
061503657
ABSTRACT:
6-Hydroxy-8-[4-[4-(2-pyrimidinyl)-piperazinyl]-butyl]-8-azaspiro[4.5]-7,9-d ione and its pharmaceutically acceptable salts and hydrates are useful in the alleviation of anxiety.
REFERENCES:
patent: 3717634 (1973-02-01), Wu et al.
patent: 4182763 (1980-01-01), Casten et al.
patent: 4409223 (1983-10-01), Riblet et al.
patent: 5431922 (1995-07-01), Nicklasson
patent: 5633009 (1997-05-01), Kenealy et al.
patent: 6008222 (1999-12-01), Salazar
Kerns, et al., "Buspirone Metabolite Structure Profile Using a Standard Liquid Chromatographic-Mass Spectrometric Protocol," J. Chromatography B, 698, 1997, pp. 133-145.
Goldthwaite, et al., "Liquid Chromatography/Chemical Reaction Interface Mass Spectrometry as an Alternate to Radioisotopes for Quantitative Drug Metabolism Studies," Anal. Chem., 68/17, 1996, pp. 2996-3001.
Jajoo, et al., "Metabolism of the Antianxiety Drug Buspirone in the Rat," Drug Metabol. And Disp., 17/6, 1989, pp. 625-633.
Jajoo, et al., Metabolism of the Antianxiety Drug Buspirone in Human Subjects, Drug Metab. and Disposition, 17/6, pp. 634-640, 1989, 6-Hydroxy Buspirone.
Mayol, et al., "Pharmacokinetics and Disposition of .sup.14 C-Buspirone HC1 After Intravenous and Oral Dosing in Man," Clin. Pharmacol. Ther., 37, p. 210, 1985.
Gammans, et al., "Metabolism and disposition of Buspirone," American J. Med., 80, Suppl. 3B, p. 41-51, 1986, is referenced on p. 1, line 23.
Vandermaelen, et al., "Inhibition of Serotonergic Dorsal Raphe Neurons by Systemic and Iontophoretic Administration of Buspirone, A Non-Benzodiazepine Anxiolytic Drug," Eur. J. Pharmacol., 129 (1-2), pp. 123-130, 1986, 5-Hydroxybuspirone.
Garattini, et al., "Notes on Buspirone's Mechanisms of Action," J. Clin. Psychiatry, 43, sec. 2, pp. 19-22, 1982.
Caccia, et al., "1-(2-Pyrimidinyl)-Piperazine as Active Metabolite of Buspirone in Man and Rat," Pharmacology, 33, pp. 46-51, 1986.
Cervo, et al., "Different Effects of Intracerebral and Systemic Administraiton of Buspirone in the Forced Swimming Test: Involvement of a Metabolite," Life Sciences, 43, pp. 2095-2102, 1988.
Martin, "1-(2-Pyrimidinyl-piperazine May Alter the Effects of the 5-HT1A Agonists in the Learned Helplessness Paradigm in Rats," Psychopharmacology, 104, pp. 275-278, 1991.
Jajoo, et al., "In Vitro Metabolism of the Antianxiety Drug Buspirone as a Predictor of Its Metabolism In Vivo," Xenobiotica, 20/8, pp. 779-786, 1990, 6-Hydroxy Buspirone.
Bristol--Myers Squibb Company
Rose Shep K.
Ryan Richard P.
LandOfFree
Anxiety method does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anxiety method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anxiety method will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1257426